Finnrick, an independent testing programme, publishes 8 assays for Lejian Biotech Peptide, and all 8 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 17 Jul 2026.
Lejian Biotech Peptide operates from China, listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/lejian-biotech-peptide.
Lejian Biotech Peptide is listed as active.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 8 | 8 passed, 0 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
These details were read from Lejian Biotech Peptide's own website on 2026-08-10. Pages consulted:
Lejian Biotech Peptide is listed as active and we hold 8 Finnrick assays (8 passing, 0 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 8 assays for Lejian Biotech Peptide, and all 8 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 17 Jul 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: LH Peptides Review, Liberty Peptides Review, Licensed Peptides Review.